PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för GSK126. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

33 hits

Bibliografisk träff 2024-03-26

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

Fischetti I, Botti L, Sulsenti R, Cancila V, Enriquez C, Ferri R, Bregni M, Crivelli F, Tripodo C, Colombo MP, Jachetti E.

Epigenomics · research-article; journal article · DOI 10.2217/epi-2023-0374

Bibliografisk träff 2024-03-06

Sirtuin 3 Mediated by Spinal cMyc-Enhancer of Zeste Homology 2 Pathway Plays an Important Role in Human Immunodeficiency Virus-Related Neuropathic Pain Model.

Zhu X, Yi H, Gu J, Liu S, Hayashi K, Ikegami D, Pardo M, Toborek M, Roy S, Li H, Levitt RC, Hao S.

Anesth Analg · journal article; research support, n.i.h., extramural · DOI 10.1213/ane.0000000000006873

Bibliografisk träff 2024-03-01

Inhibition of the histone methyltransferase EZH2 induces vascular stiffness.

Ibarrola J, Xiang RR, Sun Z, Lu Q, Hill MA, Jaffe IZ.

Clin Sci (Lond) · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1042/cs20231478

Bibliografisk träff 2023-11-27

Elevation of H3K27me3 level contributes to the radioresistance of nasopharyngeal carcinoma by inhibiting OAS1 expression.

Zhou Y, Xiao Y, Liu H, Chen Q, Zhu L, Zeng L, Liu X, Pan Y, Zhang J, Fu J, Shao C.

Am J Physiol Cell Physiol · research support, non-u.s. gov't; journal article · DOI 10.1152/ajpcell.00358.2023

Bibliografisk träff 2023-11-22

GSK-126 Attenuates Cell Apoptosis in Ischemic Brain Injury by Modulating the EZH2-H3K27me3-Bcl2l1 Axis.

Zhou T, Zhang L, He L, Lan Y, Ding L, Li L, Wang Z.

Mol Neurobiol · journal article · DOI 10.1007/s12035-023-03808-8

Bibliografisk träff 2023-08-29

Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.

Zhao G, Deng Z, Li X, Wang H, Chen G, Feng M, Zhou Y.

Exp Brain Res · journal article · DOI 10.1007/s00221-023-06693-8

Bibliografisk träff 2023-08-07

G-protein coupled receptor 5C (GPRC5C) is required for osteoblast differentiation and responds to EZH2 inhibition and multiple osteogenic signals.

Dashti P, Thaler R, Hawse JR, Galvan ML, van der Eerden BJ, van Wijnen AJ, Dudakovic A.

Bone · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bone.2023.116866

Bibliografisk träff 2023-04-03

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.

Olowosoke CB, Gbemisola O, Alaba AA, Adepoju OH, Okorie B, Odjegba PI, Ogunsanmi AO, Oke GA, Akinlolu O, Olubena TL, Bello RO, Adegboyega BB.

Appl Biochem Biotechnol · journal article · DOI 10.1007/s12010-023-04433-w

Bibliografisk träff 2023-01-31

Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and hepatic stellate cells.

Zhang Q, Jia R, Chen M, Wang J, Huang F, Shi M, Sheng H, Xu L.

J Gastroenterol Hepatol · journal article · DOI 10.1111/jgh.16126

Bibliografisk träff 2023-01-01

Dose-dependent Effects of PRC2 and HDAC Inhibitors on Cardiomyocyte Hypertrophy Induced by Phenylephrine.

Zhao Z, Lv J, Guo N, Guo Q, Zeng S, Fang Y, Chen W, Wang Z.

Curr Drug Targets · research support, non-u.s. gov't; journal article · DOI 10.2174/1389450124666230124094936

Bibliografisk träff 2022-12-05

GSK126 an inhibitor of epigenetic regulator EZH2 suppresses cardiac fibrosis by regulating the EZH2-PAX6-CXCL10 pathway.

Aziz S, Yalan L, Raza MA, Lemin J, Akram HMB, Zhao W.

Biochem Cell Biol · journal article · DOI 10.1139/bcb-2022-0224

Bibliografisk träff 2022-09-08

DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.

Zhang L, Li HT, Shereda R, Lu Q, Weisenberger DJ, O'Connell C, Machida K, An W, Lenz HJ, El-Khoueiry A, Jones PA, Liu M, Liang G.

Cancer Lett · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.canlet.2022.215899

Bibliografisk träff 2022-07-22

Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor.

Al-Hasani K, Khurana I, Mariana L, Loudovaris T, Maxwell S, Harikrishnan KN, Okabe J, Cooper ME, El-Osta A, El-Osta A.

Signal Transduct Target Ther · research support, non-u.s. gov't; research-article; journal article; case reports · DOI 10.1038/s41392-022-01034-7

Bibliografisk träff 2022-01-29

GSK-126 Protects CA1 Neurons from H3K27me3-Mediated Apoptosis in Cerebral Ischemia.

Wang Z, Su Y, Zhang L, Lan T, Li L, Qi S.

Mol Neurobiol · research-article; journal article · DOI 10.1007/s12035-021-02677-3

Bibliografisk träff 2021-06-06

Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.

Wei X, Zhang Y, Xie L, Wang K, Wang X.

Exp Ther Med · research-article; journal article · DOI 10.3892/etm.2021.10273

Bibliografisk träff 2021-01-16

EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells.

Damele L, Amaro A, Serio A, Luchetti S, Pfeffer U, Mingari MC, Vitale C.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13020319

Bibliografisk träff 2020-10-01

[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].

Liu JN, Ma ZL, Su RJ, Huang KQ.

Hua Xi Kou Qiang Yi Xue Za Zhi · research-article; journal article · DOI 10.7518/hxkq.2020.05.004

Bibliografisk träff 2020-09-07

Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma.

Park S, Jo SH, Kim JH, Kim SY, Ha JD, Hwang JY, Lee MY, Kang JS, Han TS, Park SG, Kim S, Park BC, Kim JH.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12092541

Bibliografisk träff 2020-08-14

Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.

Shankar E, Franco D, Iqbal O, Moreton S, Kanwal R, Gupta S.

Toxicol Appl Pharmacol · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.taap.2020.115200

Bibliografisk träff 2020-08-08

The Role of EZH2 Inhibitor, GSK-126, in Seizure Susceptibility.

Wang Z, Su Y, Zhuang D, Lan T.

J Mol Neurosci · journal article · DOI 10.1007/s12031-020-01677-7

Bibliografisk träff 2020-06-11

Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.

Huang B, Mu P, Yu Y, Zhu W, Jiang T, Deng R, Feng G, Wen J, Zhu X, Deng Y.

Gastric Cancer · journal article · DOI 10.1007/s10120-020-01097-x

Bibliografisk träff 2020-06-08

Diosgenin and GSK126 Produce Synergistic Effects on Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Mediating EZH2 via the Rho/ROCK Signaling Pathway.

Liu S, Rong G, Li X, Geng L, Zeng Z, Jiang D, Yang J, Wei Y.

Onco Targets Ther · research-article; journal article · DOI 10.2147/ott.s237474

Bibliografisk träff 2020-04-13

Inhibition of EZH2 attenuates inhibitory synaptic transmission via the pro-inflammatory pathway in rats.

Zhang Y, Han Y, Chen Z, Zhao D, Xia Q.

Neuropharmacology · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2020.108101

Bibliografisk träff 2019-08-30

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM.

Clin Cancer Res · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-18-4121

Bibliografisk träff 2019-02-08

EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.

Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, Wan YY, Long H, Zhu B.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-18-2395

Bibliografisk träff 2018-06-14

An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.

Bratkowski M, Yang X, Liu X.

Sci Rep · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-018-27175-w

Bibliografisk träff 2018-05-03

GSK126 alleviates the obesity phenotype by promoting the differentiation of thermogenic beige adipocytes in diet-induced obese mice.

Wu X, Wang Y, Wang Y, Wang X, Li J, Chang K, Sun C, Jia Z, Gao S, Wei J, Xu J, Xu Y, Li Q.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2018.04.073

Bibliografisk träff 2018-02-13

GSK126 (EZH2 inhibitor) interferes with ultraviolet A radiation-induced photoaging of human skin fibroblast cells.

Qin H, Zhang G, Zhang L.

Exp Ther Med · research-article; journal article · DOI 10.3892/etm.2018.5863

Bibliografisk träff 2017-10-25

PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.

Zhou J, Nie D, Li J, Du X, Lu Y, Li Y, Liu C, Dai W, Wang Y, Jin Y, Pan J.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-17-1533

Bibliografisk träff 2017-01-01

Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.

Zeng D, Liu M, Pan J.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.13773

Go to research.

Publications in the selection

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

Sirtuin 3 Mediated by Spinal cMyc-Enhancer of Zeste Homology 2 Pathway Plays an Important Role in Human Immunodeficiency Virus-Related Neuropathic Pain Model.

Inhibition of the histone methyltransferase EZH2 induces vascular stiffness.

Elevation of H3K27me3 level contributes to the radioresistance of nasopharyngeal carcinoma by inhibiting OAS1 expression.

GSK-126 Attenuates Cell Apoptosis in Ischemic Brain Injury by Modulating the EZH2-H3K27me3-Bcl2l1 Axis.

Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.

G-protein coupled receptor 5C (GPRC5C) is required for osteoblast differentiation and responds to EZH2 inhibition and multiple osteogenic signals.

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.

Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and hepatic stellate cells.

Dose-dependent Effects of PRC2 and HDAC Inhibitors on Cardiomyocyte Hypertrophy Induced by Phenylephrine.

GSK126 an inhibitor of epigenetic regulator EZH2 suppresses cardiac fibrosis by regulating the <i>EZH2-PAX6-CXCL10</i> pathway.

DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.

Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor.

GSK-126 Protects CA1 Neurons from H3K27me3-Mediated Apoptosis in Cerebral Ischemia.

Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.

EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34<sup>+</sup> Cells.

[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].

Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in <i>EZH2</i> Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma.

Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.

The Role of EZH2 Inhibitor, GSK-126, in Seizure Susceptibility.

Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.

Diosgenin and GSK126 Produce Synergistic Effects on Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Mediating EZH2 via the Rho/ROCK Signaling Pathway.

Inhibition of EZH2 attenuates inhibitory synaptic transmission via the pro-inflammatory pathway in rats.

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.

An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.

GSK126 alleviates the obesity phenotype by promoting the differentiation of thermogenic beige adipocytes in diet-induced obese mice.

GSK126 (EZH2 inhibitor) interferes with ultraviolet A radiation-induced photoaging of human skin fibroblast cells.

PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.

Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.